3 completed, 1 withdrawn. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow NOV 002: new trials by email Literature Review of NOV 002 trials Research Report on NOV 002
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Cyclophosphamide, Docetaxel, Doxorubicin - Breast Cancer | Phase 2 | Completed | University of Miami | 41 | 2007-06-04 | 2018-01-02 |
| Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer Paclitaxel, NOV-002, Carboplatin - Non Small Cell Lung Cancer | Phase 3 | Completed | Cellectar Biosciences, Inc. | 903 | 2006-11-01 | 2022-07-25 |
| Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer NOV-002, Carboplatin - Ovarian Cancer | Phase 2 | Completed | Cellectar Biosciences, Inc. | 15 | 2006-07-01 | 2015-03-10 |
| NOV-002 in Myelodysplastic Syndrome (MDS) NOV-002 - Leukemia, Myelodysplastic Syndrome | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2012-07-30 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Inflammatory Breast Neoplasms (1) · Leukemia (1) · Myelodysplastic Syndromes (1) · Ovarian Neoplasms (1) · Pericardial Effusion (1)
Cellectar Biosciences, Inc. (2) · M.D. Anderson Cancer Center (1) · University of Miami (1)
United States (3) · Canada (1) · Israel (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1) · Serbia (1) · Spain (1) · Switzerland (1) · Ukraine (1) · United Kingdom (1)
Alberto Montero, MD (1) · Carolyn Kransner, MD (1) · Gautam Borthakur, MBBS (1) · Keisuke Shirai, MD (1) · Panos Fidias, MD (1) · Thomas Lynch, MD (1)